ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RCEL Avita Medical Inc

12.69
-0.38 (-2.91%)
27 Nov 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Avita Medical Inc NASDAQ:RCEL NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.38 -2.91% 12.69 12.69 12.99 13.0137 12.6921 12.95 65,048 01:00:00

AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

25/11/2024 9:02pm

GlobeNewswire Inc.


Avita Medical (NASDAQ:RCEL)
Intraday Stock Chart


Wednesday 27 November 2024

Click Here for more Avita Medical Charts.

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 11:30 a.m. Eastern Time.

A live webcast of the fireside chat will be accessible under the Events & Presentations section of the Company's website at https://ir.avitamedical.com. A replay of the webcast will be available following the conclusion of the event.

About AVITA Medical, Inc.AVITA Medical® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

Investor & Media Contact:
Jessica Ekeberg
Phone +1-661-904-9269
investor@avitamedical.com
media@avitamedical.com

1 Year Avita Medical Chart

1 Year Avita Medical Chart

1 Month Avita Medical Chart

1 Month Avita Medical Chart